[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coherus Oncology Inc (CHRS)

Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,391
  • Shares Outstanding, K 154,501
  • Annual Sales, $ 42,170 K
  • Annual Income, $ 168,020 K
  • EBIT $ -159 M
  • EBITDA $ -155 M
  • 60-Month Beta 0.98
  • Price/Sales 4.84
  • Price/Cash Flow N/A
  • Price/Book 3.35

Options Overview Details

View History
  • Implied Volatility 205.36% (-87.82%)
  • Historical Volatility 75.38%
  • IV Percentile 54%
  • IV Rank 16.92%
  • IV High 670.52% on 11/17/25
  • IV Low 110.61% on 05/11/26
  • Expected Move (DTE 27) 0.1275 (8.98%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 410
  • Volume Avg (30-Day) 239
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 15,305
  • Open Int (30-Day) 14,593
  • Expected Range 1.2925 to 1.5475

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 3
  • High Estimate $-0.21
  • Low Estimate $-0.23
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) +42.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1300 +25.66%
on 08/17/26
1.5250 -6.89%
on 08/05/26
-0.0500 (-3.40%)
since 07/21/26
3-Month
1.1300 +25.66%
on 08/17/26
1.7350 -18.16%
on 05/27/26
-0.1500 (-9.55%)
since 05/21/26
52-Week
1.0900 +30.28%
on 11/21/25
2.6158 -45.71%
on 01/27/26
+0.2900 (+25.66%)
since 08/21/25

Most Recent Stories

More News
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology...

CHRS : 1.4200 (+7.58%)
Coherus Oncology: Q2 Earnings Snapshot

Coherus Oncology: Q2 Earnings Snapshot

CHRS : 1.4200 (+7.58%)
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI ® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck...

CHRS : 1.4200 (+7.58%)
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August...

CHRS : 1.4200 (+7.58%)
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical...

CHRS : 1.4200 (+7.58%)
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END

CHRS : 1.4200 (+7.58%)
GTBP : 0.2886 (+2.34%)
FATE : 2.33 (-4.90%)
ARTV : 10.93 (-1.89%)
IBRX : 7.79 (-0.64%)
Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts...

CHRS : 1.4200 (+7.58%)
Coherus Oncology: Q1 Earnings Snapshot

Coherus Oncology: Q1 Earnings Snapshot

CHRS : 1.4200 (+7.58%)
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking...

CHRS : 1.4200 (+7.58%)
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday,...

CHRS : 1.4200 (+7.58%)

Business Summary

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 1.5933
2nd Resistance Point 1.5167
1st Resistance Point 1.4683
Last Price 1.4200
1st Support Level 1.3433
2nd Support Level 1.2667
3rd Support Level 1.2183

See More

52-Week High 2.6158
Fibonacci 61.8% 2.0329
Fibonacci 50% 1.8529
Fibonacci 38.2% 1.6729
Last Price 1.4200
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.